BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

"Our preclinical data highlight the potential of azelaprag as a novel oral therapy for obesity," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “Our two presentations provide evidence ...

Compared with placebo, once-weekly semaglutide significantly reduced body weight, knee osteoarthritis-related pain, and improved physical function. Topline results were announced from a phase 3 ...

Expert Rev Anti Infect Ther. 2012;10(5):521-524. Despite its multifactorial etiology, [5] conventional obesity treatment or pre-vention strategies offer a blanket approach, mostly irrespective of ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter. Key ...

Continued efforts are needed to address this growing concern. Obesity: Obesity, particularly, postmenopausal obesity has been shown to have potential breast cancer promoting effects. Overweight is ...

Robust debuts by drug developers Bicara Therapeutics , MBX Biosciences, BioAge Labs and Upstream Bio are also encouraging ... metabolic diseases and obesity, providing several paths to potential ...

2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO September 25, 2024 Obesity ...

Using a national sample of medical insurance claims data from more than 17 million privately insured adults, the researchers identified patients with a diagnosis of obesity without diabetes in ...